

Reference Data

1st Quarter - Fiscal Year 2020
(April 1, 2020 to June 30, 2020)

Consolidated Earnings

- Consolidated Financial Data p. 1
- Consolidated Balance Sheets p. 2
- Consolidated P/L Statement p. 3
- Consolidated Sales Breakdown by Segment/Category p. 4
- Consolidated Operating Profit by Segment p. 4
- Consolidated Sales -
 - Leading Brands of Self-Medication Operations
 - Sales by Region p. 5
- Consolidated Sales -
 - Leading Products of Prescription Pharmaceutical Operations p. 6
- Capital Expenditure p. 7
- Depreciation and Amortization p. 7
- R&D Expenses p. 7
- Result of Major Consolidated Subsidiary
 - ◆ Taisho Pharmaceutical p. 8
- Major Subsidiaries and Affiliates p. 9
- Prescription Pharmaceutical Operations:
 - New Drug Development-Taisho Pharmaceutical p.10
- Launch of New Products p.11

Consolidated Financial Data

(Millions of yen)

	March 2020(FY2019)				March 2021(FY2020)	
	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year	1Q (4-6)	Full year E
Net sales	60,260	132,208	211,338	288,527	75,023	289,500
(YOY%)	(-2.4%)	(+2.1%)	(+5.7%)	(+10.3%)	(+24.5%)	(+0.3%)
Self-Medication operations	42,936	97,492	157,824	220,027	56,436	235,900
Prescription Pharmaceutical operations	17,323	34,716	53,513	68,500	18,587	53,600
Gross profit on sales*	41,305	87,937	134,339	180,333	47,228	180,900
Selling, general and administrative expenses	32,981	73,260	116,770	159,196	37,838	160,900
Research and development expenses	4,991	10,669	16,179	22,876	4,209	21,200
(% Sales)	(8.3%)	(8.1%)	(7.7%)	(7.9%)	(5.6%)	(7.3%)
Advertising expenses	4,800	11,753	19,557	26,046	6,107	25,600
Sales promotion expenses	5,474	13,126	20,571	27,440	5,827	25,400
Personnel expenses	6,838	14,767	23,327	31,017	8,201	32,900
Operating Profit	8,324	14,676	17,569	21,137	9,389	20,000
(YOY%)	(+2.0%)	(-13.6%)	(-37.5%)	(-32.3%)	(+12.8%)	(-5.4%)
Earnings before the amortization of goodwill and trademarks	9,263	16,930	22,523	29,470	12,399	32,600
Ordinary Profit	7,649	14,975	20,970	24,474	11,117	23,000
(YOY%)	(-37.3%)	(-34.1%)	(-42.0%)	(-40.1%)	(+45.3%)	(-6.0%)
Profit attributable to owners of parent	11,006	14,979	17,929	20,172	6,064	13,000
(YOY%)	(-19.6%)	(-64.7%)	(-65.1%)	(-58.5%)	(-44.9%)	(-35.6%)
Comprehensive income	5,301	8,694	10,483	8,470	3,537	-
(YOY%)	(-57.9%)	(-79.3%)	(-76.4%)	(-82.4%)	(-33.3%)	-
Basic EPS (yen)	137.91	187.68	224.64	252.74	75.98	162.89
Diluted EPS (yen)	137.77	187.47	224.38	252.44	75.89	162.69
BPS (yen)	8,917.17	8,961.94	8,915.54	8,887.84	8,862.95	8,963.26
Dividend per share (yen)	-	50.00	-	110.00	-	100.00
Payout ratio	-	-	-	43.5%	-	61.4%
Capital expenditure	987	2,910	5,048	9,469	2,659	20,800
Depreciation and amortization	2,391	4,942	8,345	11,366	3,673	15,700
Total assets	840,345	843,816	838,618	864,974	858,187	871,000
Shareholders' equity	741,565	734,234	731,313	739,778	736,944	746,000
Return on equity (%)**	-	-	-	2.8%	-	1.8%
Return on assets (%)**	-	-	-	2.4%	-	1.5%
Equity ratio (%)	84.7%	84.8%	84.9%	82.0%	82.4%	82.1%
Overseas sales	7,874	21,146	42,312	69,500	27,063	93,900
Overseas sales ratio (% of total sales)	13.1%	16.0%	20.0%	24.1%	36.1%	32.4%
Number of employees	8,105	9,493	9,428	9,354	9,356	-

* After provision/reversal of reserve for returned unsold goods

** Average of the beginning and year-end balance of shareholders' equity / total assets

*** First-quarter and full-year figures for FY2019 have been revised retrospectively to reflect determination of allocation of acquisition-related costs in business combinations.

<Reference>

• E = Estimates

• Full year forecasts for the fiscal year ending March 31, 2021 were announced on May 14, 2020.

Consolidated Balance Sheets

(Millions of yen)

	End of FY2019		End of FY2020/1Q		change	
	(March 31, 20)	% total	(Jun. 30, 20)	% total		
(Assets)						
I Current assets:	355,623	58.1%	352,194	41.0%	-3,429	
Cash and deposits	223,814		220,234		-3,579	
Notes and accounts receivable-trade	65,463		62,209		-3,254	
Marketable securities	14,089		14,044		-45	
Inventories	43,371		44,965		+1,594	
Other	8,884		10,740		+1,855	
II Fixed assets:	509,351	41.9%	505,993	59.0%	-3,357	
(1) Tangible fixed assets:	112,648	(11.4%)	111,535	(13.0%)	-1,112	
Buildings and structures	53,999		52,771		-1,228	
Machinery, equipment and vehicles	15,059		14,365		-693	
Land	38,170		39,287		+1,117	
Other	5,418		5,110		-307	
(2) Intangible fixed assets:	221,811	(6.6%)	214,171	(25.0%)	-7,639	
Goodwill	133,169		128,290		-4,878	
Sales rights	690		655		-34	
Trademarks	73,144		70,197		-2,947	
Software	6,570		7,061		+491	
Other	8,236		7,966		-270	
(3) Investments and other assets:	174,891	(23.8%)	180,286	(21.0%)	+5,394	
Investment securities	145,831		150,807		+4,975	
Shares of subsidiaries and affiliates	11,644		11,764		+119	
Net defined benefit assets	4,642		4,759		+117	
Deferred tax assets	11,134		11,296		+161	
Other	1,638		1,658		+19	
Total assets	864,974	100.0%	858,187	100.0%	-6,787	
(Liabilities)						
I Current liabilities:	66,456	6.7%	62,438	7.3%	-4,017	
Notes and accounts payable-trade	18,045		16,814		-1,230	
Accounts payable	15,743		16,659		+916	
Accrued income taxes	5,414		3,479		-1,934	
Provision for bonuses	3,769		2,072		-1,697	
Other	23,482		23,411		-71	
II Long-term liabilities:	58,739	4.6%	58,804	6.9%	+64	
Net defined benefit liabilities	21,029		21,114		+84	
Deferred taxes liabilities	30,042		30,347		+304	
Other	7,666		7,342		-324	
Total liabilities	125,196	11.3%	121,242	14.1%	-3,953	
(Net assets)						
I Shareholders' equity	692,768	83.5%	693,870	80.9%	+1,101	
Common stock	30,000		30,000		-	
Retained earnings	698,223		699,331		+1,107	Profit attributable to owners of parent+6,064, Payment of dividend
Treasury stock	-35,454		-35,460		-5	
II Accumulated other comprehensive income	16,605	2.8%	13,508	2.8%	-3,097	
Valuation difference on securities	20,796		23,505		+2,709	
Foreign currency translation adjustment	-1,145		-7,019		-5,874	
Remeasurements of defined benefit plans	-3,046		-2,977		+68	
III Share acquisition rights	773	0.1%	773	0.1%	-	
IV Non-controlling interests	29,630	2.2%	28,792	3.4%	-838	
Total net assets	739,778	88.7%	736,944	85.9%	-2,833	
Total liabilities and net assets	864,974	100.0%	858,187	100.0%	-6,787	

* Figures for the previous fiscal year have been revised retrospectively to reflect determination of allocation of acquisition-related costs in business combinations.

Consolidated P/L Statement

(Millions of yen)

	FY2019		FY2020		YOY change	
	1Q	% total	1Q	% total		
Net sales	60,260	100.0%	75,023	100.0%	+14,762	
Cost of sales	19,037	31.6%	27,837	37.1%	+8,800	
Gross profit on sales	41,223	68.4%	47,185	62.9%	+5,962	
Provision for sales returns	-82		-42		+39	
Gross profit	41,305	68.5%	47,228	63.0%	+5,922	
Selling, general and administrative expenses	32,981	54.7%	37,838	50.4%	+4,857	
Research and development expenses	4,991		4,209		-781	
Advertising expenses	4,800		6,107		+1,307	
Sales promotion expenses	5,474		5,827		+353	
Personnel expenses	6,838		8,201		+1,363	
Other	10,877		13,492		+2,614	
Operating Profit	8,324	13.8%	9,389	12.5%	+1,064	
Non-operating income	2,306	3.8%	1,810	2.4%	-495	
Non-operating expenses	2,981	4.9%	82	0.1%	-2,898	FY2019: Foreign exchange losses 2,932
Ordinary Profit	7,649	12.7%	11,117	14.8%	+3,467	
Extraordinary income	6,093	10.1%	1	0.0%	-6,092	FY2019: Gains attributable to phased acquisition 6,093
Extraordinary losses	3	0.0%	300	0.4%	+296	
Profit before income taxes and minority interests	13,740	22.8%	10,818	14.4%	-2,921	
Income taxes	2,414	4.0%	4,130	5.5%	+1,715	
Profit	11,325	18.8%	6,688	8.9%	-4,637	
Profit attributable to non-controlling interests	318	0.5%	623	0.8%	+304	
Profit attributable to owners of parent	11,006	18.3%	6,064	8.1%	-4,942	

Consolidated Sales Breakdown by Segment/Category

(Millions of yen)

	March 2020(FY2019)				March 2021(FY2020)	
	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year	1Q (4-6)	Full year E
Self-Medication operations	42,936	97,492	157,824	220,027	56,436	235,900
(YOY%)	(+1.0%)	(+8.6%)	(+14.5%)	(+22.2%)	(+31.4%)	(+7.2%)
Japan	34,428	74,576	112,985	147,062	28,772	138,700
Overseas	7,821	21,093	42,254	69,440	26,953	93,900
Other	687	1,822	2,584	3,523	710	3,300
Prescription Pharmaceutical operations	17,323	34,716	53,513	68,500	18,587	53,600
(YOY%)	(-10.0%)	(-12.6%)	(-13.8%)	(-15.9%)	(+7.3%)	(-21.8%)
Ethical drugs	16,682	33,699	52,160	67,022	18,194	53,000
Other	640	1,017	1,352	1,477	392	600
Total	60,260	132,208	211,338	288,527	75,023	289,500

Consolidated Operating Profit by Segment

(Millions of yen)

	March 2020(FY2019)				March 2021(FY2020)	
	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year	1Q (4-6)	Full year E
Self-Medication operations	7,032	13,056	14,117	18,694	5,483	21,800
(YOY%)	(-7.2%)	(-22.6%)	(-46.2%)	(-38.3%)	(-22.0%)	(+14.6%)
Earnings before the amortization of goodwill and trademarks	7,971	15,309	19,070	27,027	8,494	34,400
Prescription Pharmaceutical operations (YOY%)	1,605	2,381	4,743	4,144	4,466	300
	(+77.2%)	(+93.9%)	(+43.2%)	(+54.4%)	(+178.1%)	(-92.8%)
Other*	-313	-761	-1,290	-1,702	-561	-2,100
(YOY%)	(-)	(-)	(-)	(-)	(-)	(-)
Total	8,324	14,676	17,569	21,137	9,389	20,000

* The "Other" segment represents the Company (a pure holding company), which is not attributable to any reportable segment.

** Figures for FY2019 have been revised retrospectively to reflect determination of allocation of acquisition-related costs in business combinations.

Consolidated Sales - Leading Brands of Self-Medication Operations & Sales by Region

(Billions of Yen)

	March 2020(FY2019)				March 2021(FY2020)			
	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year	1Q (4-6)	YOY	Full year E	YOY
Japan	34.4	74.6	113.0	147.1	28.8	-16.4%	138.7	-5.7%
<i>Lipovitan</i> series	12.8	28.3	40.7	50.9	10.4	-18.8%	46.6	-8.4%
<i>Pabron</i> series	5.8	12.7	22.1	29.8	3.5	-39.9%	26.6	-10.9%
<i>RiUP</i> series	3.6	8.1	11.8	14.9	3.5	-2.9%	14.3	-3.7%
<i>Biofermin</i> series	2.5	5.6	8.3	10.7	2.4	-6.5%	9.9	-8.0%
<i>VICKS</i> series	0.7	1.6	3.2	4.3	0.5	-24.6%	3.7	-13.8%
GI treatment series	0.9	1.8	2.9	3.7	0.8	-12.7%	3.5	-4.8%
<i>Livita</i> series	0.8	1.7	2.5	3.4	0.8	-2.4%	3.2	-5.0%
<i>NARON</i> series	0.7	1.6	2.4	3.1	0.8	+8.7%	3.0	-3.5%
<i>Colac</i> series	0.8	1.6	2.5	3.2	0.8	-0.2%	3.0	-6.8%
Overseas	7.8	21.1	42.3	69.4	27.0	+244.6%	93.9	+35.2%
Asia	7.2	19.3	30.1	42.5	11.5	+60.5%	44.6	+5.0%
Europe and America	0.5	1.1	11.3	25.8	15.0	-	48.3	+87.5%
Others	0.7	1.8	2.6	3.5	0.7	+3.3%	3.3	-6.4%

(Rounded to the nearest hundred-million)

Lipovitan Series: Sales Breakdown

(Billions of Yen)

	March 2020(FY2019)				March 2021(FY2020)			
	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year	1Q (4-6)	YOY	Full year E	YOY
Lipovitan series	12.8	28.3	40.7	50.9	10.4	-18.8%	46.6	-8.4%
Lipovitan D	8.3	18.2	26.1	32.1	6.9	-16.9%	28.8	-10.3%
Others	4.5	10.1	14.7	18.7	3.5	-22.2%	17.8	-5.2%
(100mL other Lipovitans)	3.0	6.7	9.9	12.5	2.2	-26.8%	11.5	-7.5%
(50mL other Lipovitans)	1.5	3.4	4.8	6.3	1.3	-12.4%	6.2	-0.7%

(Rounded to the nearest hundred-million)

Consolidated Sales - Leading Brands of Prescription Pharmaceutical Operations

(Billions of Yen)

	March 2020(FY2019)				March 2021(FY2020)			
	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year	1Q (4-6)	YOY	Full year E	YOY
Edirol	6.5	13.8	20.9	27.0	7.3	+11.0%	14.4	-46.7%
Lusefi	1.9	3.2	5.1	7.1	2.6	+42.2%	9.8	+37.4%
Bonviva	1.6	3.3	5.1	6.6	1.7	+4.3%	6.9	+4.8%
LOQOA	0.9	1.9	3.0	3.9	0.9	+0.0%	4.0	+2.7%
Biofermin	1.0	2.2	3.0	3.8	1.1	+3.6%	4.0	+5.2%
Geninax	0.8	1.8	3.4	3.9	1.8	+125.5%	3.1	-21.0%
Clarith	1.1	2.1	3.4	4.3	0.5	-53.6%	2.8	-34.4%
Palux	0.8	1.7	2.5	3.1	0.6	-26.3%	2.3	-26.8%

(Rounded to the nearest hundred-million)

Consolidated: Capital Expenditure

(Millions of yen)

	March 2020(FY2019)				March 2021(FY2020)	
	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year	1Q (4-6)	Full year E
Total capital expenditure	987	2,910	5,048	9,469	2,659	20,800
Taisho Pharmaceutical	748	2,414	3,556	6,471	1,081	10,750
Production department	67	494	672	1,597	358	1,450
Research department	38	195	370	940	37	1,030
Head Office and the others	642	1,724	2,512	3,933	684	8,270
Other subsidiaries	238	495	1,492	2,998	1,578	10,050

Consolidated: Depreciation and Amortization

(Millions of yen)

	March 2020(FY2019)				March 2021(FY2020)	
	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year	1Q (4-6)	Full year E
Depreciation and amortization	2,391	4,942	8,345	12,610	3,673	15,700
Cost of sales	749	1,601	3,623	4,325	1,393	6,200
SGA expenses	1,641	3,341	4,721	8,284	2,280	9,500

* Figures for FY2019 have been revised retrospectively to reflect determination of allocation of acquisition-related costs in business combinations.

Consolidated: R&D Expenses

(Millions of yen)

	March 2020(FY2019)				March 2021(FY2020)	
	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year	1Q (4-6)	Full year E
Total R&D expenses	4,991	10,669	16,179	22,876	4,209	21,200
Self-Medication operations	1,398	2,908	4,589	6,754	1,578	7,400
Prescription Pharmaceutical operations	3,592	7,760	11,590	16,121	2,630	13,800

Result of Major Consolidated Subsidiary

Sales and earnings of Taisho Pharmaceutical

(Billions of Yen)

	March 2020(FY2019)				March 2021(FY2020)			
	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year	1Q (4-6)	YOY	Full year E	YOY
Net Sales	51.8	110.0	167.6	217.5	48.9	-5.8%	192.2	-11.6%
Self-Medication	34.6	75.4	114.2	149.2	30.3	-12.5%	138.7	-7.0%
Prescription Pharmaceutical	17.2	34.6	53.4	68.3	18.6	+7.8%	53.6	-21.6%
Operating profit	6.6	11.2	16.8	19.9	5.7	-14.4%	19.7	-0.8%
Ordinary profit	3.9	11.3	18.2	20.9	11.7	+199.5%	23.3	+11.6%
Profit	2.9	10.0	13.1	14.9	9.4	+220.3%	17.1	+14.9%

(Rounded to the nearest hundred-million)

Major Subsidiaries and Affiliates

(As of June 30, 2020)

Company	Address	Capital	Business	Ownership*
(1) Consolidated subsidiaries				%
Taisho Pharmaceutical Co., Ltd.	Tokyo, Japan	,000 Yen 29,837,892	SMG PD	100.0
MEJIRO KOSAN Co., Ltd.	Tokyo, Japan	,000 Yen 600,000	SMG	100.0
Taisho Okinawa Co., Ltd.	Okinawa, Japan	,000 Yen 50,000	SMG	100.0
Taisho M.T.C. Co., Ltd.	Tokyo, Japan	,000 Yen 400,000	SMG	60.0
Taisho Pharmaceutical Logistics Co., Ltd.	Saitama, Japan	,000 Yen 30,000	SMG	100.0
Biofermin Pharmaceutical Co., Ltd.	Hyogo, Japan	,000 Yen 1,227,000	SMG PD	63.9
Taisho Pharma Co., Ltd.	Tokyo, Japan	,000 Yen 100,000	PD	100.0
TAISHO ACTIVE HEALTH Co., Ltd.	Tokyo, Japan	,000 Yen 100,000	SMG	55.0
TOKUHON Corporation	Tokyo, Japan	,000 Yen 300,000	SMG PD	100.0
Dr. Program Co., Ltd.	Tokyo, Japan	,000 Yen 251,500	SMG	100.0
Taisho Pharmaceutical (Taiwan) Co., Ltd.	Taiwan	,000 NT\$ 200,000	SMG	100.0
Taisho Pharmaceutical California Inc.	U.S.A.	,000 US\$ 41,050	SMG	100.0
Taisho Pharmaceuticals (Philippines), Inc.	Philippines	,000 Peso 18,900	SMG	100.0
Taisho Co., Ltd. Shanghai	China	,000 CNY 132,621	SMG	100.0
Taisho Vietnam Co., Ltd.	Vietnam	,000 VND 170,754,300	SMG	100.0
Taisho Pharmaceutical (H.K.) Ltd.	China	,000 HK\$ 10,000	SMG	100.0
Osotspa Taisho Pharmaceutical Co., Ltd.	Thailand	,000 THB 100,000	SMG	60.0
Taisho Pharmaceutical R&D Inc.	U.S.A.	,000 US\$ 4,000	PD	100.0
PT. Taisho Pharmaceutical Indonesia Tbk	Indonesia	,000 rupiah 10,240,000	SMG	98.6
Taisho Pharmaceutical Singapore Private Limited	Singapore	,000 US\$ 1,365	SMG	100.0
Hoepharm Holdings Sdn.Bhd.	Malaysia	,000 MYR 32,380	SMG	100.0
Compañía Internacional de Comercio, S.A.P.I. de C.V.	Mexico	,000 MXN 122,467	SMG	100.0
Duoc Hau Giang Pharmaceutical JSC	Vietnam	,000 VND 1,307,460,710	SMG	51.0
UPSA SAS	France	,000 EUR 852,103	SMG	100.0
(2) Equity accounting method				
Yomeishu Seizo Co., Ltd.	Tokyo, Japan	,000 Yen 1,650,000	SMG	24.0

SMG=Self-Medication operations PD=Prescription Pharmaceutical operations

*Ownership: including the portion of indirect ownership

Prescription Pharmaceutical Operations: New Drug Development - Taisho Pharmaceutical

As of August 5, 2020

In Japan

Phase 3

TS-152 (Injection)

< Application	> Rheumatoid arthritis
< Development	> In-license (Licensor: Ablynx)
< Description	> Anti-TNF(Tumor Necrosis Factor)-α antibody
< Remarks	> Generic name: Ozoralizumab

Phase 2

TS-142 (Oral)

< Application	> Insomnia
< Development	> In-house

Overseas

Phase 2

TS-121 (Oral)

< Target disease	> Depression
< In-house/Licensed-in	> In-house

Phase 1

TS-134 (Oral)

< Target disease	> Schizophrenia
< In-house/Licensed-in	> In-house

TS-161 (Oral)

< Target disease	> Depression
< In-house/Licensed-in	> In-house

TS-142 (Oral)

< Target disease	> Insomnia
< In-house/Licensed-in	> In-house

Launch of New Products

As of August 5, 2020

New Products Since FY2019 Earnings Announcement (May 15, 2020)

Self-Medication Operations

Muscovado Soybean Protein (mail order)

- < Description > Product containing soybean protein, multi-grain malt made from seven types of grain (barley, foxtail millet, Japanese barnyard millet, proso millet, sorghum bicolor, black rice and rice flour) and flavorful muscovado. Product which can readily be drunk by those who are very health and beauty conscious and want to incorporate natural beauty in everyday life.
- < Launch > May 2020

Capsules for people concerned about their cholesterol and triglyceride levels (mail order)

- < Description > Soft capsule-type Food with Functional Claims (FFC) containing lycopene, a functional ingredient which lowers LDL (bad) cholesterol, and DHA and EPA, functional ingredients, which lower triglyceride levels.
- < Launch > May 2020

Lipovitan Shot for Sports

- < Description > Pre-exercise drink for people who work out and exercise. Contains β -alanine, arginine and citrulline. Drink certified by Informed-Choice, a world-renowned anti-doping certification program, that can be drunk with peace of mind by all athletes.
- < Launch > June 2020

Burdock tea with lactic acid bacteria (mail order)

- < Description > Contains burdock and lactic acid bacteria. Refreshing and healthy Rooibos Blend tea which also contains black soybeans, ginger and Japanese pepper and offers an easy way to consume lactic acid bacteria . Product which can readily be drunk by those who are very health and beauty conscious and want to incorporate natural beauty in everyday life.
- < Launch > June 2020

RIZIN SWEETY RED

- < Description > Zero caffeine, zero calorie, zero sugar energy drink in limited time-only flavor. Drink with a unique fruit taste that will get people hooked in a full-of-energy red-colored can.
- < Launch > July 2020

Launch of New Products

As of August 5, 2020

New Products Since FY2019 Earnings Announcement (May 15, 2020)

Self-Medication Operations

Lipovitan D kids Pokemon bottle

- < Description > Non-caffeine Lipovitan D kids limited edition bottle containing nutrients for healthy development such as B vitamins, calcium, and taurine, targeting children aged 5 to 14. Design featuring characters from the hugely popular TV animation Pokemon on the label and outer packaging.
- < Launch > July 2020
-

Taisho Sesamin (mail order)

- < Description > Supplement combining sesamin, a health ingredient contained in black sesame, with plant-based perilla oil and linseed oil, which contain alpha-linolenic acid. Take two tablets a day as a guide. Concentration of 25mg of sesamin, which is the equivalent of around 5,000 grains of black sesame in 2 tablets.
- < Launch > July 2020
-